Get the Stockscreener App
44.43
0.69%
-0.31
Pre-market:
44.57
0.14
+0.32%
Travere Therapeutics Inc stock is traded at $44.43, with a volume of 803.18K.
It is down -0.69% in the last 24 hours and up +10.83% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
See More
Previous Close:
$44.74
Open:
$44.39
24h Volume:
803.18K
Relative Volume:
0.39
Market Cap:
$4.13B
Revenue:
$536.20M
Net Income/Loss:
$-45.64M
P/E Ratio:
-83.08
EPS:
-0.5348
Net Cash Flow:
$-28.94M
1W Performance:
+4.32%
1M Performance:
+10.83%
6M Performance:
+28.08%
1Y Performance:
+182.99%
1-Day Range:
$44.12
$45.00
1-Week Range:
$41.32
$45.00
52-Week Range:
$13.88
$48.61
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
44.43 | 4.16B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-31-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Travere Therapeutics (TVTX) grants director 4,000 shares and 12,000 options - Stock Titan
Travere Therapeutics (TVTX) director receives stock and option awards - Stock Titan
[Form 4] Travere Therapeutics, Inc. Insider Trading Activity - Stock Titan
Travere Therapeutics (TVTX) director granted shares and 12,000 stock options - Stock Titan
Travere Therapeutics (TVTX) director granted shares and 12,000 options - Stock Titan
Travere Therapeutics (TVTX) grants director stock and options - Stock Titan
Travere Therapeutics (TVTX) investors back equity plan boost and all 2026 meeting items - Stock Titan
Travere Therapeutics Rides FILSPARI Surge After FDA Win - TipRanks
Insider Sell Alert: Timothy Coughlin Sells 3,250 Shares of Trave - GuruFocus
Travere Therapeutics (TVTX) director sells 3,250 shares in Rule 10b5-1 trade - Stock Titan
Stephens Investment Management Group LLC Acquires 121,955 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX) - The Globe and Mail
(TVTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
Armistice Capital/Steven Boyd discloses 4,897,417 TVTX shares (5.27%) - Stock Titan
Why Travere Therapeutics Stock Is Tumbling Today - TipRanks
Travere, Ligand Pharma announce FDA label expansion for Filspari - MSN
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Travere Therapeutics launches first FDA-approved therapy for rare kidney disease FSGS. - Pluang
UBS Group AG Has $16.15 Million Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2026 - BioSpace
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
State of New Jersey Common Pension Fund D Takes Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Issues New Convertible Notes to Refinance Debt - TipRanks
Travere Therapeutics Completes $525 Million 0.50% Convertible Notes Offering Led by JPMorgan, Jefferies, Leerink - TradingView
[8-K] Travere Therapeutics, Inc. Reports Material Event - Stock Titan
RTRX6388605 Bond Coupon Analysis — Rate & Payments - TradingView
Travere prices upsized $475.0 million convertible senior notes offering to refinance 2029 convertible notes - MSN
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters - Yahoo Finance
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters - The Motley Fool
MSN Money - MSN
Travere Therapeutics analysts increase their forecasts following Q1 earnings - MSN
RTRX6388605 Bond Price and Chart — FINRA:RTRX6388605 - TradingView
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Travere (TVTX) Q4 2025 Earnings Transcript - AOL.com
Travere Therapeutics Insider Sold Shares Worth $1,092,657, According to a Recent SEC Filing - Moomoo
Travere Therapeutics to Participate at Upcoming Investor ConferencesMay 7, 2026 - BioSpace
Travere Therapeutics Inc SEC Filings - Stock Titan
Travere Therapeutics plans $400M convertible notes offering - MSN
Travere Therapeutics Prices Upsized $475 Million Debt Offering - Moomoo
Travere Therapeutics Insider Sold Shares Worth $988,875, According to a Recent SEC Filing - Moomoo
Travere Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:TVTX) 2026-05-07 - Seeking Alpha
[424B5] Travere Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Travere Therapeutics (TVTX) Heads Into Q1 2026 With Sharply Narrowed Trailing Losses Testing Bull Case - Sahm
Travere Therapeutics Insider Sold Shares Worth $360,000, According to a Recent SEC Filing - Moomoo
Travere Therapeutics Insider Sold Shares Worth $1,015,086, According to a Recent SEC Filing - marketscreener.com
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes - BioSpace
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):